I-Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory
Ukuhlanzeka Okuphezulu, Ukukhiqizwa Kwezohwebo
I-Olaparib kanye Nezixhumanisi Ezihlobene:
I-Olaparib CAS 763113-22-0
I-2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid CAS 763114-26-7
1-(Cyclopropylcarbonyl)piperazine Hydrochloride CAS 1021298-67-8
I-3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Igama Lekhemikhali | Olaparib |
| Omqondofana | I-AZD-2281;KU0059436;Lynparza;4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin |
| Inombolo ye-CAS | 763113-22-0 |
| Inombolo yeCAT | I-RF-API103 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
| I-Molecular Formula | I-C24H23FN4O3 |
| Isisindo samangqamuzana | 434.46 |
| Ukuncibilika | I-Soluble ku-DMSO |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | Impushana Emhlophe Kuya Kumhlophe |
| Ukuhlonzwa nge-1H NMR | Ukuhambisana nesakhiwo |
| I-LC-MS | Ukuhambisana nesakhiwo |
| Ukuhlanzeka / Indlela Yokuhlaziya | ≥99.0% (nge-LC-MS) |
| Umswakama (KF) | ≤0.50% |
| Ukungcola Okukodwa | ≤0.50% |
| Ukungcola Okuphelele | ≤1.0% |
| Izinsimbi Ezisindayo (njenge-Pb) | ≤20ppm |
| Izinga Lokuhlola | I-Enterprise Standard |
| Ukusetshenziswa | I-API;I-PARP Inhibitor |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, I-Cardboard Drum, 25kg/Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama.
I-Olaparib (i-CAS: 763113-22-0), i-PARP-inhibitor enamandla kakhulu futhi ekhethiwe.NgoDisemba 19, 2014, i-FDA yagunyaza inoveli yesidakamizwa esilwa nomdlavuza i-Olaparib (Lynparza) ye-monotherapy ezigulini ezinomdlavuza we-ovarian othuthukile osethole okungenani imizuliswano emi-3 yokwelashwa ngamakhemikhali noma iziguli ezisolwa ngokuguquka kwe-BRCA.Ngasikhathi sinye, i-FDA igunyaze ukulinganisa nokuhlukaniswa kwamakhithi okuxilonga ukuze kutholwe uguquko ku-BRCA1 ne-BRCA2, i-BRCAanalysis CDx.I-Olaparib imithi yokuqala ye-PARP inhibitor egunyazwe yi-FDA.NgoFebhuwari 2, 2015, i-European Union Food and Drug Administration (EMA) iphinde yagunyaza i-Olaparib ukuthi ingene emakethe emazweni angama-28 e-European Union okuhlanganisa i-Iceland, i-Liechtenstein ne-Norway.Kodwa izinkomba ze-EMA ne-FDA ezigunyazwe zihluke kancane;eyokuqala ingeyezimo zokuguqulwa kofuzo ze-BRCA, kanye nokwelashwa kokunakekela iziguli ezinomdlavuza we-epithelial ovarian othuthukisiwe owake wathola imithi yokwelapha ngamakhemikhali ane-platinum futhi ebonisa impendulo futhi engaphansi kokuphindaphinda.
